36 results about "Ovary cell" patented technology

The invention relates to a cell preparation for restoring ovarian function, including amniotic mesenchymal stem cells and ovarian cells. By using amniotic mesenchymal stem cells combined with ovarian cells to make cell preparations, as well as auxiliary components for preventing the multidirectional differentiation of amniotic mesenchymal stem cells and promoting the activity and normal growth and proliferation of amniotic mesenchymal stem cells and ovarian cells, at the same time, Combined with ovarian cells, amniotic mesenchymal stem cells can maintain their stem cell characteristics for a long time, and then act on the ovary through the cytokines secreted by them combined with ovarian cells to achieve the purpose of immediate and complete restoration of ovarian function; avoid cells made of single cells In the preparation, the cell properties are unstable, resulting in unstable ovarian function repair effect, poor repair effect, and failure to completely repair ovary and other defects.

Proteonic cancer markers (PCMs) for breast, colon, liver and ovary were isolated, from the respective lysate of transformed cells, by differential centrifugation. Polyclonal antibodies were generated in mice against the (PCMs) for breast, colon, liver and ovary individually and combination thereof. Saliva from normal people was assayed by ELISA for antimixture of PCMs; breast, colon, liver and ovary cells individually. It was revealed that cancer antigen was detectable in saliva from normal people and the ELISA titer/100 μl ranged from 1:200 to 1:1600. Out of 32 normal salivas tested, ELISA titer was higher than 1:1000 in seven specimens. Those specimens were assayed by ELISA tests for individual PCM using anti-breast, anti-colon, anti-liver and anti-ovary. Each saliva specimen showed highest titer for one type of cancer antigen. Four saliva specimens showed high titers for breast PCM, two for colon one for liver. Only one saliva specimen showed high titer for ovary and colon PCMs. Thus, the invention further relates to the quantitative assessment of specific PCMs for breast, colon, liver and ovary in human saliva, by using antibodies against these markers individually.

The invention provides a high-yield baculovirus ovary cells line induced by a carcinogen, a preparation method and an application, a name of the cell line is IOZCAS-Spex12, and a preservation number is CGMCC No. 4804, the preparation method comprises the following steps: culturing beet armyworm ovary cells; and using the carcinogen to induce and converse the beet armyworm ovary cells obtained in the step 1 to obtain the high-yield baculovirus ovary cells line induced and conversed by the carcinogen; and the invention also relates to the application of high-yield baculovirus ovary cells line in baculovirus production.

The present invention relates to an engineering cell line for site-directed integration of exogenous genes, and uses thereof, wherein an identification tag is inserted into the Z4q3 region of Chinesehamster ovary cells (CHO) as host cells to obtain the cell line. According to the present invention, the engineering cell line supports the site-directed integration of exogenous genes, and can maintain the efficient and stable expression of exogenous genes for a long time.

The invention discloses a method for evaluating the genetic toxicity of drinking water through multi-genetic-end point biological group tests. According to the method, water supply plant filter outflow water and disinfected water serve as research objects, biological group genetic toxicity tests: an Ames test, an in vivo micronucleus test in mouse bone marrow polychromatic erythrocyte, a mouse sperm shape abnormality test, a hamster ovary cell micronucleus test and an SOS/umu test serve as evaluation standards, and when 3 positive results exist in the biological group genetic toxicity test, it is shown that biological genetic toxicity safety exists. The method has the following advantages that three genetic end points of gene mutation, chromosomal aberration and DNA damage are contained; test organisms comprise pronuclei, eukaryon and mammals; in-vivo and in-vitro tests are included; sexual cells and body cells are included; the detection means is relatively simple, convenient, rapid, economical and good in laboratory universality.

The invention discloses a separation and in-vitro culture method for pelodiscus sinensis ovary cells. The separation and in-vitro culture method comprises the following steps: (1) selecting sexually immature female pelodiscus sinensis; sterilizing and taking out in-vitro ovary tissues; washing the in-vitro ovary tissues with a phosphate buffering solution and washing; putting the in-vitro ovary tissues into a container; (2) carrying out digestion treatment on the washed in-vitro ovary tissues through adopting collagenase and pancreatin, and centrifuging and collecting the cells; (3) putting the collected cells into a treated cell culture container and adding a complete culture medium for culturing; (4) after the cells are proliferated and fully spread on the bottom of the cell culture container, digesting by utilizing the pancreatin and carrying out subculture or freezing preservation to obtain the pelodiscus sinensis ovary cells. The method disclosed by the invention has novel steps, is simple and convenient and has high repeatability; a pelodiscus sinensis ovary cell line with a high survival rate can be obtained.

The invention discloses a method for expressing pramlintide, and belongs to the technical field of genetic engineering. The method is characterized by comprising the following steps: conducting bacterial infection on bombyx mori ovary cells by virtue of a baculovirus multi-gene expression system, so that a baculovirus, which is capable of simultaneously expressing a human-derived amidating enzyme and the pramlintide; and then, injecting the virus into five-instar bombyx mori bodies, so that the amidating enzyme and the pramlintide are co-expressed by the bombyx mori, wherein glycine at the C terminal of the pramlintide is directly amidated by the amidating enzyme, so that the pramlintide, having an activity, is produced, and the pramlintide is purified by virtue of conventional purification means. With the application of the method disclosed by the invention, a plurality of genes can be expressed, which is conducive to co-expression of the human-derived amidating enzyme and the pramlintide; the method disclosed by the invention, which makes use of the bombyx mori bioreactor, is high in protein expression amount and is more complete in modification; and the method disclosed by the invention is short in production time, high in efficiency and low in production cost.

The invention belongs to the field of clone technology, and more specifically discloses an improved method used for cloned embryo construction. The improved method comprises following steps: S1, ovocytes are delivered into an operation droplet A, and blind absorption is adopted so as to realize denucleation; S2, cytoplasm obtained via denucleation is delivered into a dyed droplet, dyeing situations are observed directly under a fluoroscope, and the ovocytes processed via denucleation are reserved for standby application; S3, the ovocytes processed via denucleation are delivered into an operation droplet B for standing, and then are delivered into an operation droplet C containing a donor cells, one of the ovocyte is bound with one donor cell, and then is bound with another ovocyte so as to obtain a somatic cell-ovocyte-ovocyte combination; and S4, the somatic cell-ovocyte-ovocyte combination is allowed to stand in a fusion activation fluid, and then is delivered into a fusion slot for electrofusion. The improved method is simple and rapid in operation; denucleation is complete and high in efficiency; and cloning efficiency is high.

The invention provides a mythimna separata pupa ovary cell line capable of highly yielding baculovirus. The cell line is named as IOZCAS-Myse-1 and assigned the accession number CGMCC No.17282. A construction method of the cell line is provided. The method includes the following steps: step 1) obtaining mythimna separata ovary tissue; step 2) culturing the mythimna separata ovary tissue until a culture flask is filled with proliferative cells, wherein the tissue is closely attached to the bottom of the cell culture flask; and step 3) taking newly proliferative single cells, performing continuous culture until cell passage so as to obtain the cell line. The whole process is conducted under an aseptic condition. The provided cell line can be used for copying baculovirus, so that the baculovirus or baculovirus insecticide can be produced in large scale; and the cell line can also be applied to express the protein having commercial or scientific values by using a constructed baculovirus expression vector system.

The invention relates to the technical field of biological 3D printing, in particular to a method for facilitating in-vitro maturation of human immature oocytes by utilizing a 3D printing technology. The method comprises the following steps of (1) properly treating naked ova and granular cells of ovary cells; (2) performing in-vitro balanced culture of ovarian granular cells; (3) putting oocytes into the ovarian granular cells, and continuing to perform culture for 2 days; (4) preparing 3D printing ink; (5) preparing 3D printing gel; and (6) printing out follicles by adopting the 3D printing technology, putting the oocytes and an in-vitro maturation culture solution into the follicles, and performing culture for one week. According to the method, the follicles with a biochemical environment similar to that of a human body try to be simulated, and then the oocytes are quickly and accurately put into the follicles for performing artificial culture by depending on the 3D printing technology, so that the in-vitro maturation of the human immature oocytes is realized; the method depends on the 3D printing technology; and the whole process is quick and convenient, and the automation degree is high, so that the technical expense of the in-vitro maturation of the oocytes can be reduced.

The invention provides a superovulation polyvinylpyrrolidone FSH composite slow-release injection for sika deer. Four substances, such as FSH, acidic xylosidase, cellulase and gentamicin, are uniformly dispersed in polyvinylpyrrolidone so as to form a slow release agent; and according to a synergistic effect of medicines such as FSH, acidic xylosidase, cellulose, gentamicin and the like, target substances and indirectly produced nutrient substances can continuously and uniformly act on ovary cells so as to promote follicle growth and maturity; and therefore, a good effect on superovulation is achieved, and the mature ovum is high in quality. According to the dosage form, stress reaction is reduced by intravenous injection, and intense struggling caused by pain is alleviated.

The invention provides specific sgRNA for target knocking out human OC-2 genes and application. By adopting the OC-2 genes on a human genome as a target, a series of sgRNA molecules which are obtainedby a series of screening and analysis and can efficiently, specifically and accurately target the human OC-2 gene, as shown in SEQ ID NO.2 to 4. The invention also provides a lentivirus vector and alentivirus comprising the specific sgRNA at the same time. The invention also provides a method for knocking out human OC-2 genes by utilizing a CRISPR-Cas9 system, so that a stable OC-2 gene knockoutstrain can be obtained. The specific sgRNA provided by the invention can block the expression of OC-2 gene in an ovary cell by virtue of a CRISPR/Cas system, the proliferation, migration and invasioncapacity of the ovary cancer cells can be significantly inhibited, a novel direction and concept can be provided for the research and clinical treatment of the ovarian cancer, and the application prospect is good.

The invention relates to the field of gene cloning, especially to macrobrachium nipponense allatostatin (AST) gene, its amplification method and an amplification primer group. By the use of the primer group provided by the invention, an AST gene full-length cDNA sequence is cloned from macrobrachium nipponense brain tissues. The invention not only provides a theoretical basis for the research of macrobrachium nipponense ecdysis regulation, gonad maturation and oocyte maturation but also establishes a theoretical basis for the improved varieties propagation of macrobrachium nipponense.

The invention provides a separation and purification method of a Leopard Coral Grouper oogonium and identification and application thereof. By adopting the separation and purification method, the oogonium with the proportion of 85.6-90.3% can be obtained from an ovary cell suspension with the oogonium proportion of about 10% through separation and purification; the method has small damage to the cell, the obtained cell is high in activity, the operation process is simple and convenient, used instruments are common, and the method is easy to popularize and use; according to the identification method of the Leopard Coral Grouper oogonium, a hybridization display technology is adopted, a Nanos2 probe is used for marking the oogonium, and the Leopard Coral Grouper oogonium can be quickly identified; the separation and purification method of the Leopard Coral Grouper oogonium provides a technical guarantee for Leopard Coral Grouper reproductive development research and later amplification of a Leopard Coral Grouper male individual by applying an oogonial stem cells with the help of a germ cell transplantation technology.

A pharmaceutical composition for treating low testosterone comprises microcapsules the microcapsules containing live mammalian ovary cells. The ovary cells comprise ovarian theca cells in a treatment-effective amount, but not granulosa cells or without granulosa cells in amounts detrimental to the administration of testosterone. Methods of treating male subjects afflicted with low testosterone by administration of such ovary cell-containing microcapsules are also described.

The invention relates to the technical field of biology, in particular to a recombinant human adiponectin expression vector, a vector construction method and an expression method. The recombinant human adiponectin expression vector comprises a nucleotide sequence as shown in SEQ ID No. 1 and an Fc-GS plasmid. The recombinant human adiponectin expression vector construction method comprises the following steps of carrying out codon optimization according to an amino acid sequence of human adiponectin to obtain a cDNA sequence of human adiponectin, wherein the cDNA sequence of the human adiponectin is as shown in SEQ ID No. 1; designing a primer, amplifying the cDNA sequence, and recovering a target fragment after identification; and connecting the target fragment to the Fc-GS plasmid to obtain the recombinant human adiponectin expression vector. When the recombinant human adiponectin expression vector is transfected into hamster ovary cells, recombinant human adiponectin-Fc fusion protein can be stably expressed; and the method is simple, convenient and efficient.

The invention discloses a construction method, expression method and detection method for a protein tag carrier and relates to the technical field of biomarking. With Drosophila ovarian germ cell specific highly-expressed nos gene taken as an example, a cellular endogenous protein marking technique is developed, namely a protein tagging technique based on terminal exon marking; first, a transgeniccarrier with GFP (green fluorescent protein) tag sequence embedded in the terminal exon is constructed for nos gene; second, Drosophila with the transgenic carrier is prepared by means of mature transgenic technology of Drosophila; whether the expression product of the nos gene in Drosophila ovary cells is subjected to GFP fluorescence expression is detected; the technique herein facilitates theexpression pattern research for model organism Drosophila; references are provided for mammalian gene expression and positioning.

The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic ovary cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and non-cancerous disease states in ovary tissue, identifying ovary tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered ovary tissue for treatment and research.

The invention relates to the technical field of ovarian repair and discloses an ovary egg cell repairing composition and a preparation method thereof. The invention aims to solve technical problems that an existing ovary aging treatment method has a large side effect and an unclear curative effect. The invention provides an ovary egg cell repairing composition. The composition comprises a motherwort herb extract, a kudzuvine root extract, a rhizoma belamcandae extract, a peony root extract, a seaweed extract, a yeast extract, an apple fruit cell culture extract, a golden chamomile extract, a hamamelis virginiana extract, royal jelly freeze-dried powder, collagen, soy isoflavone, xanthan gum, carbomer, disodium glycyrrhizinate, chitosan and a coenzyme A. The invention further provides a preparation method of the ovary egg cell repairing composition. The composition can promote female hormone balance, regulate female reproductive system, promote pelvic blood circulation, enhance ovary immunity, enable ovary to secrete healthy ova, and achieve a purpose of effectively repairing egg cells in ovary.